Home‐based chemotherapy for stage III colon cancer patients in Thailand: Cost‐utility and budget impact analyses
Abstract Home‐based chemotherapy (HC) is a new treatment alternative to hospital‐based chemotherapy treatment (IP) and is administered via portable intravenous pumps at the patient's home. HC reduces the demand for inpatient bed capacity in hospitals and reduces the cost of an infusion. This st...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-02-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.3690 |
| _version_ | 1818877862116065280 |
|---|---|
| author | Nattanichcha Kulthanachairojana Phichai Chansriwong Nintita Sripaiboonkij Thokanit Suwannee Sirilerttrakul Nopakan Wannakansophon Suthira Taychakhoonavudh |
| author_facet | Nattanichcha Kulthanachairojana Phichai Chansriwong Nintita Sripaiboonkij Thokanit Suwannee Sirilerttrakul Nopakan Wannakansophon Suthira Taychakhoonavudh |
| author_sort | Nattanichcha Kulthanachairojana |
| collection | DOAJ |
| description | Abstract Home‐based chemotherapy (HC) is a new treatment alternative to hospital‐based chemotherapy treatment (IP) and is administered via portable intravenous pumps at the patient's home. HC reduces the demand for inpatient bed capacity in hospitals and reduces the cost of an infusion. This study takes a societal perspective while conducting the cost‐utility and budget impact analyses (BIA) of HC and IP with an mFOLFOX6 regimen on patients with stage III colon cancer. We conducted a cost‐utility analysis with a 6‐month time horizon. The parameter inputs for the model were gathered from a retrospective cohort study on patients diagnosed with stage III colon cancer at Ramathibodi Hospital, Bangkok. The resource usage of HC and IP was determined based on medical records. The per‐unit direct medical, home health service, and adverse events (AE) management costs were gathered from the standard cost list. The health outcome of treatment was measured in terms of quality‐adjusted life years. Disutility related to AE was calculated. We conducted a sensitivity analysis for the uncertainty results and performed BIA based on the societal perspective on a 1‐year time horizon. HC provided a cost‐saving of $1,513.37 per patient for the period of treatment. Thus, assuming 526 patients per year, the use of HC could achieve a cumulative annual cost‐saving of $828,436. HC is a cost‐saving strategy compared to IP for stage III colon cancer treatment. We recommend that the service reimbursement should include national standardization in chemotherapy regimens as well as practice guidelines and protocols to prevent serious AEs. |
| first_indexed | 2024-12-19T14:05:01Z |
| format | Article |
| id | doaj.art-0f28a25933554e389a0b6646e086a82f |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-12-19T14:05:01Z |
| publishDate | 2021-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-0f28a25933554e389a0b6646e086a82f2022-12-21T20:18:20ZengWileyCancer Medicine2045-76342021-02-011031027103310.1002/cam4.3690Home‐based chemotherapy for stage III colon cancer patients in Thailand: Cost‐utility and budget impact analysesNattanichcha Kulthanachairojana0Phichai Chansriwong1Nintita Sripaiboonkij Thokanit2Suwannee Sirilerttrakul3Nopakan Wannakansophon4Suthira Taychakhoonavudh5Department of Social and Administrative Pharmacy Faculty of Pharmaceutical Sciences Chulalongkorn University Bangkok ThailandMedical Oncology Unit Department of Medicine Faculty of Medicine Ramathibodi HospitalMahidol University Bangkok ThailandRamathibodi Comprehensive Cancer Center Ramathibodi HospitalMahidol University Bangkok ThailandDepartment of Nursing Ramathibodi HospitalMahidol University Bangkok ThailandDepartment of Nursing Ramathibodi HospitalMahidol University Bangkok ThailandDepartment of Social and Administrative Pharmacy Faculty of Pharmaceutical Sciences Chulalongkorn University Bangkok ThailandAbstract Home‐based chemotherapy (HC) is a new treatment alternative to hospital‐based chemotherapy treatment (IP) and is administered via portable intravenous pumps at the patient's home. HC reduces the demand for inpatient bed capacity in hospitals and reduces the cost of an infusion. This study takes a societal perspective while conducting the cost‐utility and budget impact analyses (BIA) of HC and IP with an mFOLFOX6 regimen on patients with stage III colon cancer. We conducted a cost‐utility analysis with a 6‐month time horizon. The parameter inputs for the model were gathered from a retrospective cohort study on patients diagnosed with stage III colon cancer at Ramathibodi Hospital, Bangkok. The resource usage of HC and IP was determined based on medical records. The per‐unit direct medical, home health service, and adverse events (AE) management costs were gathered from the standard cost list. The health outcome of treatment was measured in terms of quality‐adjusted life years. Disutility related to AE was calculated. We conducted a sensitivity analysis for the uncertainty results and performed BIA based on the societal perspective on a 1‐year time horizon. HC provided a cost‐saving of $1,513.37 per patient for the period of treatment. Thus, assuming 526 patients per year, the use of HC could achieve a cumulative annual cost‐saving of $828,436. HC is a cost‐saving strategy compared to IP for stage III colon cancer treatment. We recommend that the service reimbursement should include national standardization in chemotherapy regimens as well as practice guidelines and protocols to prevent serious AEs.https://doi.org/10.1002/cam4.3690colon cancercost‐utility analysishome‐based chemotherapyportable infusion pump |
| spellingShingle | Nattanichcha Kulthanachairojana Phichai Chansriwong Nintita Sripaiboonkij Thokanit Suwannee Sirilerttrakul Nopakan Wannakansophon Suthira Taychakhoonavudh Home‐based chemotherapy for stage III colon cancer patients in Thailand: Cost‐utility and budget impact analyses Cancer Medicine colon cancer cost‐utility analysis home‐based chemotherapy portable infusion pump |
| title | Home‐based chemotherapy for stage III colon cancer patients in Thailand: Cost‐utility and budget impact analyses |
| title_full | Home‐based chemotherapy for stage III colon cancer patients in Thailand: Cost‐utility and budget impact analyses |
| title_fullStr | Home‐based chemotherapy for stage III colon cancer patients in Thailand: Cost‐utility and budget impact analyses |
| title_full_unstemmed | Home‐based chemotherapy for stage III colon cancer patients in Thailand: Cost‐utility and budget impact analyses |
| title_short | Home‐based chemotherapy for stage III colon cancer patients in Thailand: Cost‐utility and budget impact analyses |
| title_sort | home based chemotherapy for stage iii colon cancer patients in thailand cost utility and budget impact analyses |
| topic | colon cancer cost‐utility analysis home‐based chemotherapy portable infusion pump |
| url | https://doi.org/10.1002/cam4.3690 |
| work_keys_str_mv | AT nattanichchakulthanachairojana homebasedchemotherapyforstageiiicoloncancerpatientsinthailandcostutilityandbudgetimpactanalyses AT phichaichansriwong homebasedchemotherapyforstageiiicoloncancerpatientsinthailandcostutilityandbudgetimpactanalyses AT nintitasripaiboonkijthokanit homebasedchemotherapyforstageiiicoloncancerpatientsinthailandcostutilityandbudgetimpactanalyses AT suwanneesirilerttrakul homebasedchemotherapyforstageiiicoloncancerpatientsinthailandcostutilityandbudgetimpactanalyses AT nopakanwannakansophon homebasedchemotherapyforstageiiicoloncancerpatientsinthailandcostutilityandbudgetimpactanalyses AT suthirataychakhoonavudh homebasedchemotherapyforstageiiicoloncancerpatientsinthailandcostutilityandbudgetimpactanalyses |